STUDY CONFIRMS SIGNIFICANTLY ELEVATED LEVELS OF CALPROTECTIN IN PATIENTS WITH SEVERE COVID-19

27. Aug 2020 | 3 min read

Moss, 27.08.20
 
Gentian Diagnostics AS is pleased to announce that the results from a study conducted in collaboration with Santa Lucia Hospital in Cartagena, Spain, are published in the scientific journal “Journal of Infection”.
 
Results from the study confirm significantly elevated levels of calprotectin in patients with severe COVID-19 and indicate the role of calprotectin in assessment of disease severity and prediction of in-hospital mortality [1].
 
The study has investigated the role of two inflammation-associated biomarkers, calprotectin and growth differentiation factor-15 (GDF-15) in prediction of disease severity and mortality in 66 hospitalised patients with SARS-CoV-2 infection. Gentian Diagnostics’ GCAL® (calprotectin) assay has been used in the study. GD 2020 08 27 GCAL study results
 
Several recent studies have reported increased levels of calprotectin in patients with severe SARS-Cov-2 infection, as well as the possibility of calprotectin to differentiate between mild and severe forms of the disease and ability to predict the need for mechanical ventilation and mortality [2-4].
 
References:
  1. de Guadiana Romualdo L.G. et al. (2020) Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: a case series. Journal of Infection, doi: https://doi.org/10.1016/j.jinf.2020.08.010 
  2. Shi H, et al. (2020) Neutrophil calprotectin identifies severe pulmonary disease in COVID-19 DOI:10.1101/2020.05.06.20093070. Preprint PMID: 32511540
  3. Zuo Y, et al. (2020) Neutrophil extracellular traps and thrombosis in COVID-19. doi:10.1101/2020.04.30.20086736. Preprint. PMID: 32511553
  4. Silvin et al. (2020) Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19 Cell, doi: https://doi.org/10.1016/j.cell.2020.08.002
 
For further information, please contact:
Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no 
Cell Phone: +47 919 05 242
 
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525
 
 
MeldingsID: 512345
UtstederID: GENT-ME
 

You may also read


Aug 19, 2021 - Kristin Hart

Invitation to presentation of second quarter results

Gentian Diagnostics ASA will present its 2021 second quarter results on August 25th at 10.00 am. The..

Jun 25, 2021 - Kristin Hart

Gentian Diagnostics was today listed on the Oslo Stock Exchange

“We made a promise to our shareholders when we were listed on Euronext Growth that we would aim for the main..